US growth 7% isn't exciting given the valuation IMO. Presumably lots of competition there too now... |
Err not familiar with this country called the US then no? |
Look at all the competition now:
It used to be schweppes massive dominance which was crushed by FEVR. All down hill from here in the UK possibly.... |
£930m market cap for a company with £360m turnover and £30m ebitda seems a lot imho. I think we are just witnessing a super growth highly valued stock come back to earth. Probably fair valuation of around 700p imo. |
Some might argue the news was already priced in. |
Not bad at all against the current market backdrop to get a flat results period, but the market was clearly expecting more and overall growth not a zero..
Not holding yet, but will keep watching.. |
Sales falling in UK and Europe. Competition hurting perhaps. There seem to be lots of new upstarts. |
Thought it was positive overall.Surely oversold? |
Interesting update.. |
26.03.2024 - We are confident that the benefit of the actions taken in 2023, along with a focus on further profit-driving initiatives in 2024, including continued execution of our pricing strategy across key markets, will drive a significant improvement in gross margin in 2024 and allow for further recovery in 2025 and beyond.
Now let us see how they actually performed in H1, the share price tell a different story down -50%, but potential opportunity timing if the update is positive, rate cuts widely expected on the 18th in the US.. |
10 Jul 24 1013.0 Strong Bear Tenkan/Kijun Cross
05 Jul 24 1048.0 Strong Bear Chikou Span Cross
04 Jul 24 1053.0 Strong Bear Kijun Sen Cross
29 May 24 1048.0 Bear Kumo Breakout
23 May 24 1145.0 Weak Bear Senkou Span Cross
free stock charts from uk.advfn.com
free stock charts from uk.advfn.com |
Evening all...
Next week:
Fevertree, Half Year Results, Thursday 12 September
Aarin Chiekrie, equity analyst, Hargreaves Lansdown: Last investors heard, Fevertree LON:FEVR had been scooping up market share across its regions which had helped to increase sales. Innovation across Rum, Vodka and other spirits has helped boost the group’s leading position in the UK, and growth in Europe continues to grow ahead of the broader mixer category.
Fevertree’s already said it’s comfortable with full-year expectations, which at the time of the last update in June pointed towards 8% sales growth and underlying cash profit margins of around 15%. Markets will be keeping a close eye on whether these targets are still on track when half-year results are announced next week, with market forecasts currently suggesting this could be a slight stretch. |
Would imagine the possible introduction of a glass tax by the new government may be another headwind for them. Does anyone know where the majority of their bottles are made?, assume a third party in the UK but could also be some in the US. |
MAJOR SHAREHOLDING
This information was last updated on 30/06/2024.
NAME
If anyone fancies updating the Major Shareholder info in the heading the table’s below:
%
Lindsell Train Investment Mgt 15.40
Capital Group 9.00
Fundsmith 6.16
Nordflint Capital Partners 5.07
Tim Warrillow 4.78
Charles Rolls 4.36
Baillie Gifford 3.31 |
In the back of my mind in making an investment in Fevertree, I can’t help but think what an obvious takeover target this would make for Diageo. It’s like a perfect match for them.
Salty. |
Been watching and waiting to get an entry point for my first foray into Fevertree. Bought £20k worth this morning. Will buy more if price starts to pick up and we see some momentum building.
Salty |
Thanks phil |
Barclays cuts Fevertree Drinks target to 1,270 (1,300) pence - 'equal weight' |
 Fever-Tree can fizz again, says Deutsche Bank
Premium mixer business Fever-Tree (FEVR) is trading at an ‘attractive valuation’ despite the challenging backdrop, says Deutsche Bank.
Analyst Deirdre Mullaney retained her ‘buy’ recommendation but reduced the target price from £16 to £14.50 on the stock, which rose 2% to 913p on Monday after a full-year preview. The shares have tumbled 9% year-to-date.
Despite the downbeat sentiment towards the business, Mullaney said that she ‘continues to believe Fever-Tree is well positioned to capitalise on the long-term premium mixer opportunity given its strong brand equity and large white space opportunity overseas’.
Falling costs, new supply agreements and supply chain improvements will allow ‘strong margin recovery than consensus expects in outer years’.
However, Mullaney said that near-term the ‘stock will struggle given the challenging market backdrop’, leading her to revise down full-year 2024 and 2025 expectations that reflect a ‘negative weather impact over the summer and weak global spirits market’.
The shares trade on 23.1 times price to earnings for 2025 which Mullaney said ‘is an attractive valuation given the long-term growth potential’.
Citywire.com |
This one is strangely overpriced. Premium drinks when the average guy is cutting expenses seems not a huge growing market to me. Also, the increase in receivables is concerning and might cause issues down the line.On the other side, great tonic water. Great Brand for drinks, not to invest in ( at the moment) |
DGE not helping? |
Jefferies cuts Fevertree price target to 1,000 (1,150) pence - 'hold' |
US recession looming, FEVR might have a few issues going forward.. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
